Among patients with stage IV disease, bivariate analyses indicated that EGFR testing was associated with younger age, Hispanic and API heritages, being married, having private/military/other insurance, being a non-smoker, having adenocarcinoma or other/non-specified carcinoma, having no comorbidities and living at least two months after cancer diagnosis (Table 3). This evidence concerns the gene EGFR and adenocarcinoma.